Mangaluru: Basheer buried amidst tears and prayers; family appeals for peace

Bengaluru, Jun 20: Former Chief Minister and Congress Legislative Party leader Siddaramaiah has slammed BJP leader and former Congress MP and MLA H Vishwanath for blaming him for not getting MLC ticket.

Siddaramaiah said, "H Vishwanath is neither a fool nor intelligent, that's why he's blaming me for not getting ticket. He is in BJP and I'm in congress how will I influence his ticket."

He also slammed Chief Minister B. S. Yediyurappa, "Yediyurappa is toothless to speak to PM and asking for funds which need to be allotted to Karnataka including 5,049 crores, which 15th finance Commission suggested."

"No pro-people schemes must be stopped including Indira canteen, Yediyurappa thinks Indira canteen will bring good name to me that's why this government is trying to stop it," he added.

He was speaking after a protest organised at Mysuru against the hike in fuel prices.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Bengaluru, May 14: As many as 22 new cases have been reported in Karnataka taking the total number of positive cases in the state to 981. 

The new cases include five in Bengaluru Urban - all with a contact history, four each in Gadag - with history of travel to Ahemadabad, Mandya with travel history to Mumbai, Maharashtra and Bidar - with three from containment zone and one with travel history to Mumbai, three from Davangere and one each from Belagavi and Bagalkote.

Meanwhile, two more deaths have been reported in the state on Thursday morning taking the total toll to 35. This is apart from a non-COVID-19 death.

An 80-year-old resident of Dakshina Kannada, got admitted at private hospital following a stroke. She was shifted to the icu on confirmation for Covid-19 at a designated hospital on April 26. She died on Thursday due to septic shock.

Another 60-year-old male, resident of Ananthapur in Andhra Pradesh, admitted at Victoria Hospital in Bengaluru with severe pneumonia and respiratory distress died due to cardiac arrest on Thursday morning. He had hypotension and Diabetes Mellitus, according to the morning health bulletin.

Sources in Victoria Hospital said this person was the first patient to undergo clinical trial for plasma therapy. He was infused plasma on Monday. However, his condition continued to remain the same.